Browse by author
Lookup NU author(s): Professor Helen ReevesORCiD
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
© 2025 The Author(s)Hepatocellular carcinoma (HCC) is a major cause of cancer deaths worldwide. It is often diagnosed at advanced stages, requiring systemic therapies like sorafenib, lenvatinib, atezolizumab-bevacizumab, and tremelimumab-durvalumab. However, disparities in access to systemic therapies for HCC remain a major global challenge, particularly in low- and middle-income countries where high drug costs, regulatory delays, and limited healthcare infrastructure impede treatment. Drawing on international experience, we highlight the urgent need for coordinated advocacy and innovative programs—such as Project Orbis and expedited approval pathways—to improve drug availability. Multisectoral collaboration among patient groups, clinicians, policymakers, and industry is essential to ensure equitable access to life-saving therapies and to reduce the burden of HCC worldwide.
Author(s): Allaire M, Da Fonseca LG, Sanduzzi-Zamparelli M, Choi W-M, Monge C, Liu K, Leibfried M, Manes S, Maravic Z, Mishkovikj M, Bruix J, Reeves HL, Salem R, Sangro B
Publication type: Review
Publication status: Published
Journal: The Lancet Regional Health - Europe
Year: 2025
Volume: 57
Print publication date: 01/10/2025
Online publication date: 31/07/2025
Acceptance date: 17/07/2025
ISSN (electronic): 2666-7762
Publisher: Elsevier Ltd
URL: https://doi.org/10.1016/j.lanepe.2025.101408
DOI: 10.1016/j.lanepe.2025.101408
Data Access Statement: The data that support the findings of this study are available on request from the corresponding author MA
